Skip to main content
. 2015 Jan 15;10(1):e0115372. doi: 10.1371/journal.pone.0115372

Figure 3. GDF-15.

Figure 3

A. Plasma GDF-15 protein levels in patients with metastatic testicular cancer (n = 41) prior to start of bleomycin- and cisplatin-based chemotherapy, compared to healthy age-matched males (n = 10); B. Plasma GDF-15 protein levels before, during and after completion of bleomcyin- and cisplatin-based chemotherapy for testicular cancer. The sample at c1d1 is drawn before initiation of chemotherapy. (*) p < 0,05 compared to baseline value or indicated time-point.